StocktoriaBriaCell Therapeutics Corp. BCTXL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-16.22
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$27.2M | -$33.3M | -$23.3M | -$15.3M | -$7.0M |
| Net income | -$26.3M | -$4.8M | -$20.3M | -$26.8M | -$13.8M |
| Operating cash flow | -$28.2M | -$24.1M | -$23.7M | -$12.5M | -$7.8M |
| Free cash flow | — | -$24.6M | — | — | — |
| Total assets | $21.6M | $5.9M | $27.2M | $42.6M | $58.0M |
| Shareholders' equity | $17.3M | -$2.7M | -$3.8M | $10.3M | $27.7M |
| Ratios | |||||
| Return on assets | -121.5% | -81.6% | -74.7% | -63.0% | -23.8% |
| Return on equity | -151.8% | 178.5% | 537.5% | -259.8% | -49.9% |
| Current ratio | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -16.22 (distress)
- Working capital / assets 0.737
- Retained earnings / assets -5.162
- EBIT / assets -1.257
- Equity / liabilities 4.017
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001610820 · as of 2025-07-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.